Award

National Institute of Biomedical Imaging and Bioengineering 2R01EB032349-06

Harnessing the Radiochelation Chemistry of Theranostic, Rare Earth Isotopes

Recipient

University of Wisconsin-Madison, Department of Chemistry

Award Amount

$416,311.00

Ceiling

$416,311.00

Awarded

May 21, 2026

Identifier

2R01EB032349-06

NIH awarded a grant to University of Wisconsin-Madison to develop advanced radiopharmaceuticals using theranostic rare earth isotopes for improved cancer diagnosis and therapy, aiming to enhance clinical adoption and patient outcomes.

Description

This NIH grant project focuses on developing next-generation radiopharmaceuticals using theranostic isotope pairs combining diagnostic and therapeutic radionuclides for personalized medicine. The research aims to create functional radiopharmaceuticals for a pentad of isotopes (18F, 44Sc, 86Y, 177Lu, 161Tb) with improved chelation chemistry compatible with one-step radiosynthesis and clinical application, validated in preclinical mouse models of various cancers.

View original record